PLASMA ANDROGEN LEVELS IN MEN AFTER ORAL ADMINISTRATION OF TESTOSTERONE OR TESTOSTERONE UNDECANOATE

1975 ◽  
Vol 79 (2) ◽  
pp. 366-374 ◽  
Author(s):  
E. Nieschlag ◽  
J. Mauss ◽  
A. Coert ◽  
P. Kićović
Keyword(s):  
Oral Administration ◽  
Thin Layer ◽  
Free Testosterone ◽  
Peripheral Circulation ◽  
Plasma Testosterone ◽  
Testosterone Undecanoate ◽  
Striking Increase ◽  
Layer Chromatography ◽  
Effective Medication ◽  
Androgen Levels

ABSTRACT Plasma testosterone and androstenedione levels in men were measured after oral administration of free testosterone and testosterone undecanoate. Both androgens were determined by simultaneous, specific radioimmunoassays after separation and isolation by thin layer chromatography. While free unesterified testosterone had no effect on plasma androgen levels, a striking increase of both testosterone and androstenedione levels was noted after administration of testosterone undecanoate, which is otherwise only achieved by parenteral testosterone application. This effect of testosterone undecanoate is probably due to absorption via the lymph rather than via the portal vessels so that peripheral circulation is reached before metabolism in the liver. Testosterone undecanoate promises to be an effective medication for oral androgen replacement.

Treatment of anorchia with oral testosterone undecanoate: pharmacodynamics and clinical effectiveness

1980 ◽  
Vol 95 (2) ◽  
pp. 244-250 ◽  
Author(s):  
J. Weil ◽  
F. Bidlingmaier ◽  
O. Butenandt ◽  
W. G. Sippell ◽  
W. Baumgartner ◽  
...  
Keyword(s):  
Single Dose ◽  
Oral Administration ◽  
Sexual Maturation ◽  
Peak Level ◽  
Clinical Effectiveness ◽  
Bone Age ◽  
Plasma Testosterone ◽  
Testosterone Undecanoate ◽  
Axillary Hair ◽  
Specific Radio

Abstract. The pharmacodynamics of plasma testosterone (T) and androstenedione (A) levels were studied in ten hypogonadal boys after oral administration of testosterone undecanoate (TU). Plasma T and A levels were measured by specific radio-immunoassays. Six hours after a single dose of 120 mg TU, there was a significant increase (P < 0.005) in plasma T and A with a median T peak level of 940 ng/100 ml. Furthermore, twelve agonadal boys treated with a mean dose of 60 mg TU/day were examined over a period of 18–24 months. During this therapy, plasma T and A levels were significantly higher than before (P < 0.005), whereas plasma levels of LH and FSH did not decrease significantly. With the exception of one anorchic boy, all patients showed signs of sexual maturation, such as growth of pubic and axillary hair, and steady development of bone age during oral TU treatment.

THE EFFECT OF ACTH ON PLASMA TESTOSTERONE AND ANDROSTENEDIONE CONCENTRATIONS IN PATIENTS WITH PROSTATIC CARCINOMA

1976 ◽  
Vol 81 (2) ◽  
pp. 310-320 ◽  
Author(s):  
Teresa H. Cowley ◽  
B. G. Brownsey ◽  
M. E. Harper ◽  
W. B. Peeling ◽  
K. Griffiths
Keyword(s):  
Plasma Concentration ◽  
Thin Layer ◽  
Thin Layer Chromatography ◽  
Endocrine Therapy ◽  
Prostatic Carcinoma ◽  
Plasma Testosterone ◽  
Testosterone Concentration ◽  
Carcinoma Of The Prostate ◽  
Specific Radioimmunoassay ◽  
Layer Chromatography

ABSTRACT The effect of Synacthen (β1–24-corticotrophin) on plasma testosterone and 4-androstene-3,17-dione concentrations in untreated patients with prostatic carcinoma, and in patients receiving endocrine therapy is described. An established specific radioimmunoassay was used for the measurement of testosterone, and a radioimmunoassay for 3-androstene-3,17-dione using thin layer chromatography has been developed. Administration of Synacthen resulted in a fall in testosterone in untreated patients, but a rise in 4-androstene-3,17-dione was observed. The plasma concentration of testosterone in all treated patients increased after administration of Synacthen. An increased concentration of plasma 4-androstene-3,17-dione was also observed in these treated patients after Synacthen, but the magnitude of the response was not significantly different from that of untreated patients. The work provides further evidence that in the patient being treated with oestrogen for carcinoma of the prostate a rise in plasma testosterone concentration will result from an increased secretion of ACTH.

Plasma Testosterone Using Sephadex LH-20 and Saturation Analysis by Competitive Protein Binding

1973 ◽  
Vol 10 (1-6) ◽  
pp. 115-119 ◽  
Author(s):  
Daphne M. Lawrence ◽  
G. I. Swyer
Keyword(s):  
Protein Binding ◽  
Thin Layer ◽  
Thin Layer Chromatography ◽  
Plasma Testosterone ◽  
Short Columns ◽  
Competitive Protein Binding ◽  
Layer Chromatography

A method Tor measuring plasma testosterone using separation on short columns of Sephadex LH-20 and competitive protein binding is described. This is more reliable and practicable than methods using paper or thin layer chromatography separation and Sephadex LH-20 can be re-used after washing.

The metabolism of some folates in the rat

1975 ◽  
Vol 33 (3) ◽  
pp. 299-308 ◽  
Author(s):  
J. R. G. Beavon ◽  
J. A. Blair
Keyword(s):  
Body Weight ◽  
Oral Administration ◽  
Thin Layer ◽  
Thin Layer Chromatography ◽  
Small Extent ◽  
Methyl Group ◽  
Tetrahydrofolic Acid ◽  
Layer Chromatography

1. A number of folates labelled with 14C were administered orally to rats, at various doses, and urinary, faecal and hepatic folates examined.2. 10-Formylpteroylmonoglutamic acid (10CHO—PGA) entered the folate pool very slowly, and is thought to be relatively ineffective in nutrition.3. 10-Formyl[2-14C]tetrahydrofolic acid (10CHO—[2-14C]THF) entered the folate pool very rapidly. 5-Methyl[2-14C]tetrahydrofolate (5CH3—[2-14C]THF) was the major urinary folate.4. 5-Formyl[2-14C]tetrahydrofolic acid (5CHO—[2-14C]THF) entered the folate pool only to a small extent. 5CHO—[2-14C]THF, given intravenously, produced no urinary 5CH3—[2-14C]THF in the first 6 h.5. 10-Methylidyne[2-14C]tetrahydrofolic acid was metabolized to an extent which was dependant on the dose. At doses of 3 and 30 μg/kg body-weight, 5CH3—[2-14C]THF represented 5·4 and 20% respectively of urinary folates and for 10CHO—[2-14]PGA, the values were 16% of total urinary folates after the higher dose, and 78·5% after the lower dose.6. Results obtained for the metabolism of 5CH3—THF varied depending on the position of the labelling: 514CH3–THF gave no labelled urinary folate, the methyl group being lost rapidly. When 5CH3—[2-14C]THF was given, it appeared as the major urinary folate.7. Folates found in the liver after oral administration of labelled folates were identified by thin-layer chromatography; only folate monoglutamates were identified.

TESTOSTERONE UNDECANOATE: A NEW ORALLY ACTIVE ANDROGEN

1975 ◽  
Vol 80 (1) ◽  
pp. 179-187 ◽  
Author(s):  
C. Hirschhäuser ◽  
C. R. N. Hopkinson ◽  
G. Sturm ◽  
A. Coert
Keyword(s):  
Gas Chromatography ◽  
Oral Administration ◽  
Replacement Therapy ◽  
Elevated Plasma ◽  
Testosterone Undecanoate ◽  
Androgen Replacement Therapy ◽  
Normal Men ◽  
Orally Active ◽  
Elevate Plasma ◽  
Androgen Levels

ABSTRACT Oral testosterone undecanoate (TU) in arachis oil has been evaluated with a view to its possible use as a means of androgen replacement therapy. A single 100 mg dose was found to elevate plasma androgen levels and urinary 17-ketosteroid excretion in 6 normal men. Ninety mg/day and 60 mg/day doses taken by a hypogonadal man resulted in sustained levels of androgen which appeared physiological when measured by radioimmunoassay without chromatography. However, upon separation of the steroids by chromatography it was found that much of the androgen present was in fact dihydrotestosterone not testosterone. Both TU and dihydrotestosterone undecanoate were detected in plasma by gas chromatography and it is suggested that the ester is absorbed as such from the intestine and the unesterified steroid subsequently released by hydrolysis. The convenience of oral administration, the resulting prolonged elevated plasma androgen levels and the probable lack of deleterious effects on the liver may render oral TU of value where androgen replacement therapy is indicated.

scholarly journals Endogenous Testosterone Levels Are Associated with Risk of Type 2 Diabetes in Women without Established Comorbidity

2020 ◽  
Vol 4 (6) ◽  
Author(s):  
Jon J Rasmussen ◽  
Christian Selmer ◽  
Signe Frøssing ◽  
Morten Schou ◽  
Jens Faber ◽  
...  
Keyword(s):  
Type 2 Diabetes ◽  
Free Testosterone ◽  
Sex Hormone Binding Globulin ◽  
Plasma Testosterone ◽  
Total Testosterone ◽  
Incident Type ◽  
Increased Risk ◽  
The Impact ◽  
Androgen Levels

Abstract Purpose The impact of endogenous androgen levels on the risk of type 2 diabetes in women remains uncertain. The objective was to investigate associations between endogenous androgen levels and risk of type 2 diabetes in young women without established comorbidity. Methods In this retrospective cohort study, women aged 18 to 50 years who underwent measurement of plasma testosterone, dehydroepiandrosterone-sulfate (DHEA-S), dihydrotestosterone (DHT), and sex hormone-binding globulin (SHBG) for the first time from January 2007 to December 2015 were included. Androgens were analyzed using tandem liquid chromatography mass spectrometry. Women with established comorbidity were excluded, using Danish healthcare registries. We calculated incidence rate ratios (IRRs, 95% confidence intervals) of type 2 diabetes according to quartiles of plasma androgens using multivariate Poisson regression models. Results A total of 8876 women, with a mean ± SD age of 38.5 ± 4.6 years and a median (interquartile range [IQR]) follow-up duration of 8.1 (6.6-9.4) years, were eligible for analyses. During 69 728 person-years, 69 women were diagnosed with type 2 diabetes. Women in the highest quartile of plasma total testosterone and calculated free testosterone displayed increased risk of type 2 diabetes compared with the lowest quartile: IRR 1.97 (1.01; 3.85), P = .048 and IRR 7.32 (2.84; 18.83), P &lt; .001. SHBG was inversely associated with type 2 diabetes, Q4 versus Q1; IRR 0.06 (0.02; 0.21), P &lt; .001. Plasma DHEA-S and DHT were not associated with incident type 2 diabetes. Conclusions Higher levels of plasma total and free testosterone were associated with increased risk of type 2 diabetes among women.

Thin-Layer Chromatography

1965 ◽  
Author(s):  
H. R. Bolliger ◽  
M. Brenner ◽  
H. Gänshirt ◽  
Helmut K. Mangold ◽  
H. Seiler ◽  
...  
Keyword(s):  
Thin Layer ◽  
Thin Layer Chromatography ◽  
Layer Chromatography
Sign in / Sign up

Export Citation Format

Share Document